1-6 of 6
Julia Stieglmaier
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Blinatumomab for minimal residual disease in adults with B-cell precursor acute lymphoblastic leukemia

Clinical Trials & Observations
Nicola Gökbuget, Hervé Dombret, Massimiliano Bonifacio, Albrecht Reichle, Carlos Graux, Christoph Faul, Helmut Diedrich, Max S. Topp, Monika Brüggemann, Heinz-August Horst, Violaine Havelange, Julia Stieglmaier, Hendrik Wessels, Vincent Haddad, Jonathan E. Benjamin, Gerhard Zugmaier, Dirk Nagorsen, Ralf C. Bargou
Journal: Blood
Blood (2018) 131 (14): 1522–1531.
https://doi.org/10.1182/blood-2017-08-798322
Published: 2018
Includes: Supplemental data
Journal Articles

Phase 2 study of the bispecific T-cell engager (BiTE) antibody blinatumomab in relapsed/refractory diffuse large B-cell lymphoma

Clinical Trials & Observations
Andreas Viardot, Marie-Elisabeth Goebeler, Georg Hess, Svenja Neumann, Michael Pfreundschuh, Nicole Adrian, Florian Zettl, Martin Libicher, Cyrus Sayehli, Julia Stieglmaier, Alicia Zhang, Dirk Nagorsen, Ralf C. Bargou
Journal: Blood
Blood (2016) 127 (11): 1410–1416.
https://doi.org/10.1182/blood-2015-06-651380
Published: 2016
Includes: Supplemental data
Journal Articles

Long-Term Outcomes after Blinatumomab Treatment: Follow-up of a Phase 2 Study in Patients (Pts) with Minimal Residual Disease (MRD) Positive B-Cell Precursor Acute Lymphoblastic Leukemia (ALL)

Nicola Gökbuget, MD, Hervé Dombret, MDPhD, Massimiliano Bonifacio, MD, Albrecht Reichle, MD, Carlos Graux, MDPhD, Christoph Faul, MD, Helmut Diedrich, MD, Max S. Topp, MD, Monika Brüggemann, MD, Heinz A. Horst, MD PhD, Julia Stieglmaier, PhD, Hendrik Wessels, MD, Vincent Haddad, MSc, Gerhard Zugmaier, MD, Dirk Nagorsen, MD, Ralf C Bargou, MD
Journal: Blood
Blood (2015) 126 (23): 680.
https://doi.org/10.1182/blood.V126.23.680.680
Published: 2015
Journal Articles

Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma with the Bispecific T-Cell Engager (BiTE ® ) Antibody Construct Blinatumomab: Primary Analysis Results from an Open-Label, Phase 2 Study

Andreas Viardot, Mariele Goebeler, Georg Hess, Svenja Neumann, Michael Pfreundschuh, Nicole Adrian, Florian Zettl, Martin Libicher, Evelyn Degenhard, Julia Stieglmaier, Alicia Zhang, Dirk Nagorsen, Ralf C. Bargou
Journal: Blood
Blood (2014) 124 (21): 4460.
https://doi.org/10.1182/blood.V124.21.4460.4460
Published: 2014
Journal Articles

BLAST: A Confirmatory, Single-Arm, Phase 2 Study of Blinatumomab, a Bispecific T-Cell Engager (BiTE ® ) Antibody Construct, in Patients with Minimal Residual Disease B-Precursor Acute Lymphoblastic Leukemia (ALL)

Nicola Goekbuget, Hervé Dombret, Massimiliano Bonifacio, Albrecht Reichle, Carlos Graux, Violaine Havelange, Eike C. Buss, Christoph Faul, Monika Bruggemann, Arnold Ganser, Julia Stieglmaier, Hendrik Wessels, Vincent Haddad, Gerhard Zugmaier, Dirk Nagorsen, Ralf C. Bargou
Journal: Blood
Blood (2014) 124 (21): 379.
https://doi.org/10.1182/blood.V124.21.379.379
Published: 2014
Journal Articles

Open-Label Phase 2 Study Of The Bispecific T-Cell Engager (BiTE ® ) Blinatumomab In Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma

Andreas Viardot, Mariele Goebeler, Michael Pfreundschuh, Nicole Adrian, Martin Libicher, Evelyn Degenhard, Julia Stieglmaier, Alicia Zhang, Dirk Nagorsen, Ralf C. Bargou
Journal: Blood
Blood (2013) 122 (21): 1811.
https://doi.org/10.1182/blood.V122.21.1811.1811
Published: 2013